Dr. Vinod Chaudhari is a Medicinal Chemist, received his PhD in Synthetic Organic/Carbohydrate Chemistry from University of Pune, Pune and subsequently moved to University Joseph Furrier (CNRS), Grenoble, France for a Post-Doctoral training on Synthetic Organic Chemistry. He has over 12 years of Synthetic and Medicinal Chemistry research experience in Indian Industries. He has worked at Lupin Research Park Pune, Aurigene Discovery Technology Ltd and Zydus Research Centre, prior to joining CSIR-IMTECH Jan 2019. Vinod has experience in leading drug discovery teams that successfully delivered several preclinical/clinical development candidates. He has experience in working with various target classes including GPCRs, Ion channels and Kinases, across different therapeutic areas like Metabolic disorders, Oncology, Respiratory diseases, Inflammation, and Neurosciences.

At CSIR-IMTECH his research group focus will be on new drug discovery in the different therapeutic areas like of Oncology, Antimicrobial resistance, Infectious and Neglected diseases. Currently working on design and synthesis of novel small molecules targeting different targets for the therapeutic area of Respiratory infectious diseases particularly tuberculosis (TB), Antimicrobial resistance (AMR), Virology and Oncology. His research focus is also on total synthesis of biologically active natural/unnatural products and development of green methodologies.

• Diversity in the ligand binding pocket of HapR attributes to its uniqueness towards several inhibitors with respect to other homologues-A structural and molecular perspective. Sen et al; International Journal of Biological Macromolecules, 2023, 233, 12395.
• One-Pot Domino Reaction: Direct Access to Polysubstituted 1,4- 2 Benzothiazine 1,1-Dioxide via Water-Gas Shift Reaction Utilizing DMF/H2O; Sharma et al. The Journal of Organic Chemistry, 2023, 88 (1), 701.
• Discovery of a Potent and Selective PI3Kδ Inhibitor (S)-2,4-Diamino-6-((1-(7-fluoro-1-(4-fluorophenyl)-4-oxo-3-phenyl-4H-quinolizin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile with Improved Pharmacokinetic Profile and Superior Efficacy in Hematological Cancer Models. Shukla, M. R., et al.; Journal of Medicinal Chemistry, 2020, 63 (23), 14700.
• Free spermidine evokes superoxide radicals that manifest toxicity. Kumar, V., et al Elife, 2022, 11, e77704.
• Identification of a Novel Series of Orexin Receptor Antagonists with a Distinct Effect on Sleep Architecture for the Treatment of Insomnia. BetschartC., et al; Journal of Medicinal Chemistry, 2013, 56 (19), 7590–7607.
• An Efficient Synthesis of D-erythro- and D-threo-Sphingosine from D-Glucose: Olefin Cross-Metathesis Approach. Chaudhari, V. D., et. al.; Organic Letters,2005, 7, 5805.

• Substituted tricyclic heterocyclic compounds as metallo-beta-lactamase inhibitors. WO2022254464A1.
• Arylalkylamine Compounds as Calcium Sensing Receptor Modulators. WO2014/033604, US2015/239827, US2016/075655, US2017/0137371, EP2888225, AU2013/308081, CA2882039, CN104583177, IN421MUN2015, JP2015/528462, HK1211916.
• Substituted Morpholines as Modulators for The Calcium Sensing Receptor. WO2012/120476, US2013/345213, US2016/0250219, EP2683697, AU2012/226375, CA2828415, ZA2013/06576, IN2011KOL31720110310.
• Diaza-spiro[5,5]undecanes as Orexin Receptor Antagonists; WO2011/076747, US2012/2264748, EP2516439, JP2013/515033, AR079553, CN102762567, TW2011/32642, UY33125; Novartis AG, Switzerland.
• Disubstituted Heteroaryl-Fused Pyridines.WO2011/076744, US2012/258973, EP251637, CN102762560, IN2009/02664, JP2013/515032.
• Di/tri-Aza-Spiro-C9-C11 Alkanes. WO2012/101487, US2012/165331, AR084430.